drugset / Trial / NCT00293696

Casodex/Zoladex Biomarkers in Localised Prostate Cancer

NCT00293696

Phase 4 Completed 30 enrolled Tampere University
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate anti-androgen (bicalutamide) induced biological and molecular changes in prostate comparison to chemical castration induced (goserelin) ones

Timeline

Start
2004-10
Primary completion
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Bicalutamide Other / unclassified 150 mg
Subject Goserelin Other / unclassified 3.6 mg

Indications